信迪利单抗辅助治疗切除后高危肝细胞癌:一项随机对照2期试验
这项在中国六家医院开展的多中心、开放标签、随机对照2期试验纳入198例伴微血管侵犯的肝细胞癌术后患者,按1:1随机接受信迪利单抗辅助治疗或主动监测。中位随访23.3个月后,信迪利单抗组中位无复发生存期27.7个月,主动监测组15.5个月(HR 0.534,95%CI 0.360-0.792,P=0.002)。信迪利单抗组12.4%患者发生3或4级治疗相关不良事件。
要点
- 伴微血管侵犯的肝细胞癌术后患者中,信迪利单抗辅助治疗较主动监测显著延长无复发生存期。
- 信迪利单抗组中位无复发生存期27.7个月,主动监测组15.5个月,HR 0.534(95%CI 0.360-0.792,P=0.002)。
- 信迪利单抗组12.4%患者发生3或4级治疗相关不良事件,常见为丙氨酸氨基转移酶升高(5.2%)和贫血(4.1%)。
核心结论
- 信迪利单抗辅助治疗较主动监测显著延长伴微血管侵犯的肝细胞癌术后患者的无复发生存期,总生存期差异需进一步随访确认,这些发现支持免疫检查点抑制剂作为此类高危患者有效辅助治疗的潜力。
研究设计与样本
- 多中心、开放标签、随机对照2期试验,在中国六家医院开展,纳入伴微血管侵犯的肝细胞癌术后患者198例,按1:1随机分配至信迪利单抗组(n=99)或主动监测组(n=99)。
- 信迪利单抗组接受静脉注射,每3周一次,共8个周期。
- 主要终点为意向治疗人群的无复发生存期,关键次要终点包括总生存期和安全性。
- 招募时间为2020年9月1日至2022年4月23日。
主要发现
- 中位随访23.3个月后,信迪利单抗组中位无复发生存期27.7个月,主动监测组15.5个月(HR 0.534,95%CI 0.360-0.792,P=0.002)。
- 信迪利单抗组12.4%患者发生3或4级治疗相关不良事件,最常见为丙氨酸氨基转移酶升高(5.2%)和贫血(4.1%)。
- 总生存期差异需进一步随访确认。
临床怎么用
- 原文未据此给出推荐。
局限性
- 总生存期差异需进一步随访确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatocellular carcinoma (HCC), particularly when accompanied by microvascular invasion (MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy is considered a promising avenue. This multicenter, open-label, randomized, controlled, phase 2 trial was conducted at six hospitals in China to assess the efficacy and safety of adjuvant sintilimab, a programmed cell death protein 1 inhibitor, in these patients. Eligible patients with HCC with MVI were randomized (1:1) into the sintilimab or active surveillance group. The sintilimab group received intravenous injections every 3 weeks for a total of eight cycles. The primary endpoint was recurrence-free survival (RFS) in the intention-to-treat population. Key secondary endpoints included overall survival (OS) and safety. From September 1, 2020, to April 23, 2022, a total of 198 eligible patients were randomly allocated to receive adjuvant sintilimab (n = 99) or undergo active surveillance (n = 99). After a median follow-up of 23.3 months, the trial met the prespecified endpoints. Sintilimab significantly prolonged RFS compared to active surveillance (median RFS, 27.7 versus 15.5 months; hazard ratio 0.534, 95% confidence interval 0.360-0.792; P = 0.002). Further follow-up is needed to confirm the difference in OS. In the sintilimab group, 12.4% of patients experienced grade 3 or 4 treatment-related adverse events, the most common of which were elevated alanine aminotransferase levels (5.2%) and anemia (4.1%). These findings support the potential of immune checkpoint inhibitors as effective adjuvant therapy for these high-risk patients. Chinese Clinical Trial Registry identifier: ChiCTR2000037655 .
引用
- Wang K, Xiang YJ, Yu HM, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med. 2024. PMID: 38242982. doi:10.1038/s41591-023-02786-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。